Sara Jiménez-González
Research Subjects
Sara Jiménez-González has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Antonio-Javier Chamorro
Department of Internal Medicine, Hospital General Universitario de Salamanca-IBSAL, Universidad de Salamanca, 37007 Salamanca, Spain
1 shared publication - David Puertas-Miranda
Department of Internal Medicine, University Hospital of Salamanca, 37007 Salamanca, Spain
1 shared publication Erik Gabriel Díaz-Ávila
Department of Medicine, University de Salamanca , Salamanca
1 shared publicationFabiola Campo-Lobato
Servicio de Medicina Interna, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, España
1 shared publication- Francisco Josué Cordero-Pérez
Department of Internal Medicine, Complejo Asistencial de Zamora , Zamora
1 shared publication Isabel González-Fernández
Servicio de Medicina Interna, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, España
1 shared publication
Latest Publications
- 26 May 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Pneumonia and in-hospital mortality in ANCA-associated vasculitis: a nationwide population-based registry study in Spain
Objectives: To determine the incidence, predictors and impact of pneumonia among hospitalized patients with ANCA-associated vasculitis (AAV). Methods: A nationwide retrospective analysis of Spanish hospital discharges (2016–2023) identified all AAV admissions and coexisting pneumonia using ICD-10 codes. Outcomes included pneumonia incidence, intensive care unit (ICU) utilization, length of stay, temporal trends, in-hospital mortality and case fatality rate (CFR). Illness severity was classified using the severity of illness (SOI) and risk of mortality (ROM) indices. Multivariable logistic regression was used to identify independent predictors of in-hospital mortality. Results: Among 12 378 AAV hospitalizations, 1280 (10.3%) had pneumonia. Pneumonia was associated with higher ICU admission rates (13.5% vs 6.5%), longer stays (median 22 vs 17 days), and greater in-hospital mortality (14.9% vs 4.4%) than those without pneumonia (all P < 0.001). In-hospital AAV mortality increased significantly over time (incidence rate ratio [IRR], 1.13 per year; P < 0.001). Viral pneumonia cases in AAV surged during the COVID-19 pandemic (2021–2022), declined by 2023, and showed a significant overall increase across the study period (IRR, 1.46; 95% CI: 1.38, 1.54; P < 0.001). In-hospital CFR rose sharply with extreme SOI (27.1% vs 18.7%; P < 0.001). Pneumonia was an independent predictor of death (odds ratio 1.97; 95% CI: 1.63, 2.37; P < 0.001), and a higher ROM was strongly associated with mortality risk. Conclusion: Around 1 in 10 hospitalizations with AAV develop pneumonia, which is associated with higher odds of in-hospital death and greater ICU utilization. Pneumonia is strongly associated with worse outcomes in AAV, supporting the need for proactive infection prevention and early treatment in AAV.
- 26 May 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Pneumonia and in-hospital mortality in ANCA-associated vasculitis: a nationwide population-based registry study in Spain
Objectives: To determine the incidence, predictors and impact of pneumonia among hospitalized patients with ANCA-associated vasculitis (AAV). Methods: A nationwide retrospective analysis of Spanish hospital discharges (2016–2023) identified all AAV admissions and coexisting pneumonia using ICD-10 codes. Outcomes included pneumonia incidence, intensive care unit (ICU) utilization, length of stay, temporal trends, in-hospital mortality and case fatality rate (CFR). Illness severity was classified using the severity of illness (SOI) and risk of mortality (ROM) indices. Multivariable logistic regression was used to identify independent predictors of in-hospital mortality. Results: Among 12 378 AAV hospitalizations, 1280 (10.3%) had pneumonia. Pneumonia was associated with higher ICU admission rates (13.5% vs 6.5%), longer stays (median 22 vs 17 days), and greater in-hospital mortality (14.9% vs 4.4%) than those without pneumonia (all P < 0.001). In-hospital AAV mortality increased significantly over time (incidence rate ratio [IRR], 1.13 per year; P < 0.001). Viral pneumonia cases in AAV surged during the COVID-19 pandemic (2021–2022), declined by 2023, and showed a significant overall increase across the study period (IRR, 1.46; 95% CI: 1.38, 1.54; P < 0.001). In-hospital CFR rose sharply with extreme SOI (27.1% vs 18.7%; P < 0.001). Pneumonia was an independent predictor of death (odds ratio 1.97; 95% CI: 1.63, 2.37; P < 0.001), and a higher ROM was strongly associated with mortality risk. Conclusion: Around 1 in 10 hospitalizations with AAV develop pneumonia, which is associated with higher odds of in-hospital death and greater ICU utilization. Pneumonia is strongly associated with worse outcomes in AAV, supporting the need for proactive infection prevention and early treatment in AAV.
- Open Access
- 23 April 2026
- Published by Sociedad Espanola de Medicina Interna (SEMI) in Revista Española de Casos Clínicos en Medicina Interna
- Vol. 11 (1) , 25-29
Fibrosis retroperitoneal probablemente relacionada con enfermedad por IgG4 y positividad antifosfolípidica
Se presenta un caso de fibrosis retroperitoneal (FRP) probablemente relacionada con enfermedad por IgG4(IgG4-RD), asociada a positividad antifosfolípida no confirmatoria de síndrome antifosfolípido (SAF). Mujerde 57 años con antecedentes de cardiopatía isquémica, psoriasis e hipotiroidismo, que presentaba claudicaciónintermitente y dolor lumbar crónico con signos de arteriopatía periférica. La angio-TAC mostrótrombosis aórtica infrarrenal y periaortitis y PET-TC fue compatible con FRP activa. Además, el estudio deautoinmunidad mostró anticoagulante lúpico positivo y anticardiolipina IgM débilmente positiva. FRP activaprobablemente asociada a IgG4-RD y positividad antifosfolípida sugestiva de SAF. Recibió tratamiento concorticoides y rituximab con buena evolución. Este caso ilustra la complejidad diagnóstica de las enfermedadessistémicas y el riesgo vascular añadido de estas.
- 23 April 2026
- Published by Sociedad Espanola de Medicina Interna (SEMI) in Revista Española de Casos Clínicos en Medicina Interna
- Vol. 11 (1) , 25-29
Open AccessFibrosis retroperitoneal probablemente relacionada con enfermedad por IgG4 y positividad antifosfolípidica
Se presenta un caso de fibrosis retroperitoneal (FRP) probablemente relacionada con enfermedad por IgG4(IgG4-RD), asociada a positividad antifosfolípida no confirmatoria de síndrome antifosfolípido (SAF). Mujerde 57 años con antecedentes de cardiopatía isquémica, psoriasis e hipotiroidismo, que presentaba claudicaciónintermitente y dolor lumbar crónico con signos de arteriopatía periférica. La angio-TAC mostrótrombosis aórtica infrarrenal y periaortitis y PET-TC fue compatible con FRP activa. Además, el estudio deautoinmunidad mostró anticoagulante lúpico positivo y anticardiolipina IgM débilmente positiva. FRP activaprobablemente asociada a IgG4-RD y positividad antifosfolípida sugestiva de SAF. Recibió tratamiento concorticoides y rituximab con buena evolución. Este caso ilustra la complejidad diagnóstica de las enfermedadessistémicas y el riesgo vascular añadido de estas.